On behalf of Agenus and OncoDaily, we would like to to invite you to an Agenus- sponsored educational event titled “Advances in the Immunotherapy of Cold Tumors: Colorectal cancer, Ovarian Cancer and Sarcomas – Focus on BOT-BAL (botensilimab-balstilimab)”.
The event is to take place in Paris, on Sunday, March 1st, 2026.
Aligned with the recent expansion of the French government’s AAC program (Autorisation d’Accès Compassionnel), now covering full reimbursement of BOT/BAL in three indications, this event will present and discuss BOT/BAL data in colorectal cancer (late and early-stage disease), ovarian cancer and sarcomas, presented and discussed by prominent thought leaders. The event is intended for the education of French medical oncologists, residents, and pharmacists. Agenus is the sole sponsor, with OncoDaily managing the overall communication framework of this event.
Refreshments and meals will be provided. Accommodation in Paris for 1 night, if needed, will also be provided, as well as reimbursement for travel expenses to attend the event.
FR
Au nom de Agenus et de OncoDaily, nous avons le plaisir de vous inviter à une réunion scientifique sponsorisée par Agenus, intitulée : “Avancées en immunothérapie des tumeurs dites “froides” : cancers colorectaux, cancers de l’ovaire et sarcomes – focus sur BOT/BAL (botensilimab – balstilimab)”.
Cette réunion se tiendra à Paris, le dimanche 1er mars 2026. Le lieu précis vous sera communiqué prochainement.
Dans le contexte récent de l’évolution du programme français d’Autorisation d’Accès Compassionnel (AAC), incluant désormais BOT/BAL dans trois indications, cette réunion sera l’occasion de présenter et de discuter les données cliniques disponibles sur BOT/BAL dans le cancer colorectal (stades avancés et précoces), le cancer de l’ovaire et les sarcomes. Les échanges seront animés par des experts français reconnus dans ces domaines.
Cet événement s’adresse aux oncologues médicaux, internes et pharmaciens hospitaliers.
Agenus est le sponsor exclusif de cette réunion, tandis que OncoDaily assure la coordination et le cadre de communication de l’événement.
Des rafraîchissements et des repas seront offerts. Une nuit d’hébergement à Paris, si nécessaire, ainsi que le remboursement des frais de déplacement, seront également proposés afin de faciliter votre participation.
SPEAKERS
| Images | Name |
|---|---|
 | Prof. Isabelle Ray-Coquard, MD, PhD(France)President ENGOT |
 | Jean-Yves Blay (France)Professor of Medical Oncology, Director of the Centre Leon Bérard, |
 | Italiano Antoine (France)Head of Early Phase Trials Unit at Institut Bergonié |
 | Dhan Chand (USA)Vice President of Research at Agenus |
 | Alexander Eggermont (Netherlands)Professor of Oncological Surgery, Princess Maxima Center and Utrecht University Medical Center |
AGENDA
| Time | Speaker | |
|---|---|---|
AGENDA - Agenus educational event - Paris, Sunday, March 1st, 2026 | ||
Part 1 - Colorectal Cancer | ||
08:00 | Welcome Breakfast | |
08:30 | Faculty Introductions - Meeting Purpose | |
08:40 | Current Treatment of Neoadjuvant and Metastatic CRC: Approaches and Goals | |
09:00 | Immunotherapy of CRC: Approaches and Goals | |
09:30 | BOT-BAL. The Science of Botensilimab, a 2nd Generation Anti-CTLA 4 mAb | |
09:50 | Coffee break | |
10:00 | Phase 1 and Phase 2 BOT-BAL in solid tumors (advanced and early disease) | |
10:20 | BOT-BAL in the Immunotherapy of Metastatic CRC a with Case Presentations | |
10:40 | BOT-BAL in the neoadjuvant CRC setting a with case presentations | |
11:00 | Management of colitis, a common IMAE [Immune-mediated Adverse event] | |
11:10 | The Phase 3 BATTMAN study | |
11:15 | Visualization of BOT-BAL videos (testimonials) | |
11:35 | Access to BOT-BAL: France’s AAC and Patient-Named programs – Patient selection criteria, logistics of access, physician’s responsibilities, safety and efficacy monitoring | |
11:55 | General discussion on BOT-BAL in CRC, with selected standard of care case presentations– Place of BOT-BAL in the CRC armamentarium – Issues and barriers for its adoption | |
12:55 | Final Remarks | |
13:00 | LUNCH | |
Part 2 – Ovarian Cancer and Sarcomas | ||
14:30 | Current Treatment of Platinum-resistant and Platinum-refractory ovarian cancer [PROC] – Clinically relevant outcomes and patient’s goals – The role of neoadjuvant therapy | |
| 14: 50 | What is the role of immunotherapy in ovarian cancer? - Issues and pitfalls? | |
15:05 | BOT-BAL in PROC – Evidence to date a with case presentations | |
15:25 | Current Treatment of Soft-tissue sarcomas – The role of neoadjuvant therapy | |
15:40 | What is the role of immunotherapy in sarcomas? - Issues and pitfalls | |
15:50 | BOT-BAL in the immunotherapy of sarcomas – evidence to date a with case presentations | |
16:55 | General discussion on BOT-BAL in ovarian cancer and sarcomas - Access to BOT-BAL in ovarian cancer and sarcomas - Place of BOT-BAL in the ovarian and sarcoma armamentaria - Activity thresholds to overcome - Issues and barriers for its adoption | |
17:25 | Final Remarks | |
17:30 | COFFEE AND DEPARTURES | |
Register Here
For more information, please contact Claire Nolan at claire.nolan@agenusbio.com